Glaukos Sales Surge 36% in Q4, Reaffirms 2026 Guidance
Event summary
- Glaukos anticipates preliminary Q4 2025 net sales of $143 million, a 36% increase year-over-year.
- Full-year 2025 net sales are projected at $507 million, up 32% compared to 2024.
- iDose TR net sales are expected to contribute approximately $45 million in Q4 and $136 million for the full year.
- The company holds $283 million in cash and cash equivalents as of the end of Q4 2025.
- Glaukos reaffirmed its 2026 revenue guidance range of $600 million to $620 million.
The big picture
Glaukos' strong performance underscores the growing demand for minimally invasive glaucoma surgery (MIGS) and dropless therapies, a trend driven by an aging population and a desire for less invasive treatment options. The reaffirmed 2026 guidance suggests confidence in continued market adoption of iDose TR, but the company's valuation will be sensitive to any signs of slowing growth or increased competition in the rapidly evolving ophthalmic space. The company's substantial cash reserves provide flexibility for future acquisitions or pipeline expansion.
What we're watching
- Product Adoption
- The continued success of iDose TR will be critical for sustaining Glaukos’ growth trajectory, and the Q4 and full-year numbers provide an early indication of its market penetration.
- Competitive Landscape
- How Glaukos navigates the evolving ophthalmic pharmaceutical and medical technology landscape, particularly with potential competitors entering the dropless therapy space, will determine its long-term market share.
- Pipeline Progression
- The pace at which Glaukos advances its broader pipeline of novel therapies, beyond iDose TR and Epioxa, will be a key indicator of its future growth potential and ability to maintain a competitive edge.
